Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as trovostobart
TBS-2025 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | TBS-2025 administered at multiple, escalating dose levels as monotherapy |
| Dose Optimization | EXPERIMENTAL | TBS-2025 administered at 2 or more dose levels as monotherapy |
| Name | Type | Description |
|---|---|---|
| TBS-2025 | BIOLOGICAL | TBS-2025 is a fully human IgG1-kappa monoclonal antibody that binds specifically to the hVISTA-ECD and blocks interaction with endogenous VISTA ligands. |
Inclusion Criteria: * Documented r/r AML (BM blasts ≥5%) with NPM1-mutation * Received, and has progressed, recurred, or is intolerant of approved/effective therapeutic options, including treatment with a menin inhibitor, for r/r AML, or declines treatment with these therapies. Relapsed disease is ...